Top

Osteoporosis International

Published in:

01-02-2008 | Original Article

Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women

Authors: H.-Y. Zhao, J.-M. Liu, G. Ning, Y.-J. Zhao, Y. Chen, L.-H. Sun, L.-Z. Zhang, M.-Y. Xu, J.-L. Chen

Published in: Osteoporosis International | Issue 2/2008

Abstract

Summary

Serum IGF-I level was negatively correlated with OPG and OPG/RANKL ratio, but positively correlated with RANKL. Serum OPG level in the highest quintile of IGF-I was significantly lower than that in the lowest. We conclude that the effect of IGF-I on bone remodeling may be mediated by the OPG/RANKL system.

Introduction

Insulin-like growth factor I (IGF-I) is an important factor in coupling bone remodeling, activating both formation and resorption. Compared with the many studies on the role of IGF-I in bone formation, the information regarding its effects on bone resorption is limited and conflicting. The balance of the two peptides produced by osteoblasts, osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL), is critical for the bone resorption process. Our study was designed to analyze the relationships of serum concentrations of IGF-I with OPG, RANKL, OPG/RANKL ratio as well as BMDs in healthy Chinese women.

Methods

BMDs at lumbar spine and proximal femur in 504 pre- and postmenopausal women were measured by DXA. Serum levels of IGF-I, OPG and RANKL were also measured. Pearson’s correlation and partial correlation analysis, ANOVA, covariance analysis and stepwise multiple regression analysis were used as appropriate.

Results

Age was negatively correlated with serum levels of IGF-I (r = −0.702, p < 0.001). IGF-I was negatively correlated with OPG and OPG/RANKL ratio, but positively correlated with RANKL. The relationship between IGF-I and BMDs disappeared after adjustment for age. In postmenopausal women, IGF-I was lower in women with osteoporosis than in those with normal BMD (p = 0.056), but no differences were found among OPG, RANKL and OPG/RANKL ratio. Serum levels of OPG in the highest quintile of IGF-I were significantly lower than those in the lowest quintile of IGF-I, while no difference was found in RANKL. In the multiple regression analysis model, serum levels of IGF-I were the main determinants of the bone mass in Chinese women.

Conclusions

In conclusion, the relationship between decreasing IGF-I and BMDs in healthy Chinese women influenced by age, whereas the effect of IGF-I on bone remodeling (bone resorption) may be mediated by the OPG/RANKL system.

Canalis E (1997) Insulin-like growth factors and osteoporosis. Bone 21:215–216PubMedCrossRef

Zhao G, Monier-Faugere MC, Langub MC et al (2000) Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141:2674–2682PubMedCrossRef

Jian GJ, Gronowicz G, Ledgard F et al (2000) Phenotypic characterization of transgenic mice with bone directed overexpression of IGF-I. J Bone Miner Res 15:S157

Bikle D, Majumdar S, Laib A et al (2001) The skeletal structure of IGF-I deficient mice. J Bone Miner Res 16:1320–1330CrossRef

Miyakoshi N, Kasukawa Y, Linkhart TA et al (2001) Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142:4349–4356PubMedCrossRef

Friedlander AL, Butterfield GE, Moynihan S et al (2001) One year of IGF-I treatment does not affect BMD, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab 86:1496–1503PubMedCrossRef

Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinol 142:5050–5055CrossRef

Lacey DL, Timms E, Tan HL (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRef

Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Res 7:613–635CrossRef

10.

Simonet WS, Lacey DL, Dunstan CR (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRef

11.

Ma YL, Cain RL, Halladay DL et al (2001) Catabolic effects of continuous human PTH in vivo is associated with sustained stimulation of RANKL and inhibition of OPG and gene-associated bone formation. Endocrinology 142:4047–4054PubMedCrossRef

12.

Hofbauer LC, Gori F, Riggs BL et al (1999) Stimulation of OPGL and inhibition of OPG by glucocorticoids in human osteoblastic lineage cells. Endocrinology 140:4382–4389PubMedCrossRef

13.

Lee S, Lorezo J (1999) PTH stimulates trance and inhibits OPG mRNA. Endocrinology 140:3552–3561PubMedCrossRef

14.

Burguera B, Hofbauer LC, Thomas T et al (2001) Leptin reduces ovariectomy induced bone loss in rats. Endocrinology 142:3546–3553PubMedCrossRef

15.

Szulc P, Hofbauer LC, Delmas PD (2001) OPG serum levels in men: correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab 86:3162–3165PubMedCrossRef

16.

Yakar S, Rosen CJ (2003) From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med (Maywood) 228:245–252

17.

Ueland T (2005) GH/IGF-I and bone resorption in vivo and in vitro. Eur J Endocrinol 152:327–332PubMedCrossRef

18.

Rubin J, Ackert-Bicknell CL, Zhu L et al (2002) IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87:4273–4279PubMedCrossRef

19.

Gorny G, Shaw A, Oursler MJ (2004) IL-6 LIF and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro. Exp Cell Res 294:149–158PubMedCrossRef

20.

Liu JM, Zhao HY, Ning G et al (2005) Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20–75. Calcif Tissue Inter 76:1–6CrossRef

21.

WHO Scientific Group Research on the menopause in the 1990’s (1996) A report of the WHO Scientific Group. World health Organization, Geneva, Switzerland 866:1–79

22.

WHO Assessment of fracture risk, its application t screening for postmenopausal osteoporosis (1994) Report of a WHO study Group. WHO Technical Report Series, No.843

23.

Langlois JA, Rosen CJ, Visser M et al (1998) Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham heart study. J Clin Endocrinol Metab 83:4257–4262PubMedCrossRef

24.

Martini G, Valenti R, Giovani S et al (2001) Influence of insulin-like growth factor-I and leptin on bone mass in healthy postmenopausal women. Bone 28:113–117PubMedCrossRef

25.

Seck T, Scheppach B, Scharla S et al (1998) Concentration of insulin-like growth factor (IGF)-I and II in iliac crest bone matrix from pre- and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J Clin Endocrinol Metab 83:2331–2337PubMedCrossRef

26.

Seck T, Bretz A, Krempien R et al (1999) Age-related changes in insulin-like growth factor I and II in human femoral cortical bone: lack of correlation with bone mass. Bone 1999:387–393CrossRef

27.

Poehlman ET, Toth MJ, Ades PA et al (1997) Menopause-associated changes in plasma lipids, insulin-like growth factor-I, and blood pressure: a longitudinal study. Eur J Clin Invest 27:322–326PubMedCrossRef

28.

Romagnoli E, Minisola S, Carnevale V et al (1993) Effect of estrogen deficiency on IGF-I plasma levels: relationship with bone mineral density in perimenopausal women. Calcif Tissue Int 53:1–6PubMedCrossRef

29.

Ravn P, Overgaard K, Spencer EM et al (1995) Insulin-like growth factors I, and II in healthy women with and without established osteoporosis. Eur J Endocrinol 132:313–319PubMedCrossRef

30.

Sugimoto T, Nishiyama K, Kuribayashi F et al (1997) Serum levels of insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 12:1272–1279PubMedCrossRef

31.

Liu JM, Zhao HY, Ning G et al (2007) IGF-I as an early marker for low bone mass or osteoporosis in pre- and postmenopausal women. J Bone Miner Metab (in press)

32.

Bikle D, Majumdar S, Laib A et al (2001) The skeletal structure of IGF-I deficient mice. J Bone Miner Res 16:1320–1330CrossRef

33.

Fiorelli G, Formigli L, Zecchi Orlandini S et al (1996) Characterization and function of the receptor for IGF-I in human preosteoclastic cells. Bone 18:269–276PubMedCrossRef

34.

Hill PA, Reynolds JJ, Meikle MC (1995) Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function. Endocrinology 136:124–131PubMedCrossRef

35.

Wang YM, Nishida S, Elalieh HZ et al (2006) Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res 21:1350–1358PubMedCrossRef

36.

Lum L, Wong BR, Josien R (1999) Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dentritic cell survival. J Biol Chem 274:13613–13618PubMedCrossRef

37.

Theoleyre S, Kwan Tat S, Vusio P et al (2006) Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK. Biochem Biophy Res Commun 347:460–467CrossRef

Title: Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women
Authors: H.-Y. Zhao
J.-M. Liu
G. Ning
Y.-J. Zhao
Y. Chen
L.-H. Sun
L.-Z. Zhang
M.-Y. Xu
J.-L. Chen
Publication date: 01-02-2008
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 2/2008
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-007-0440-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2008

Underdeveloped trabecular bone microarchitecture is detected in children with cerebral palsy using high-resolution magnetic resonance imaging

Which bone mass measures discriminate adolescents who have fractured from those who have not?

Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003

Intrauterine programming of bone. Part 2: Alteration of skeletal structure

Improvement of Ca balance by Fructus Ligustri Lucidi extract in aged female rats

Tai chi for osteoporosis: a systematic review